Tumor phenotype conversion was dependent on a CD8+ T cell phenotype with ability to divide rapidly (memory-like) and secrete IFNγ (effector-like), suggesting this as a design criterion/goal for T cell therapies as well as a matching patient selection metric. Here, IFNG is linked to neoplasm.